📊 BTCY Key Takeaways
Investment Thesis
Biotricity exhibits severe financial distress with negative stockholders' equity of -$34.2M, indicating the company is technically insolvent. Despite strong gross margins of 81.3%, the company burns cash operationally (-$698K in FCF) and cannot cover basic operating expenses, with a critical liquidity crisis evidenced by a current ratio of 0.21x and only $256.4K in cash.
BTCY Strengths
- Exceptional gross margin of 81.3% indicates strong pricing power and product unit economics
- Positive operating income of $996.7K demonstrates some operational profitability at the EBIT level
- Medical device sector with potential for recurring revenue if commercial traction improves
BTCY Risks
- Negative stockholders' equity of -$34.2M represents technical insolvency and existential bankruptcy risk
- Severe liquidity crisis with current ratio of 0.21x and only $256.4K cash against $38.2M total liabilities
- Negative operating cash flow of -$698K and free cash flow of -$727.8K indicates unsustainable cash burn with no clear path to profitability
- Net loss of -$2.1M on $11.7M revenue demonstrates inability to convert gross profits into bottom-line profitability
- Interest coverage ratio of 0.4x indicates inability to service debt obligations from operating earnings
Key Metrics to Watch
- Cash burn rate and cash runway until depletion
- Operating cash flow trajectory toward positive territory
- Revenue growth rate and path to achieving positive net income
- Stockholders' equity recovery through capital raises or debt restructuring
- Debt service obligations and refinancing risk
BTCY Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BTCY Profitability Ratios
BTCY vs Healthcare Sector
How BIOTRICITY INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BTCY Balance Sheet & Liquidity
BTCY 5-Year Financial Trend
5-Year Trend Summary: BIOTRICITY INC.'s revenue has grown significantly by 307% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.66 indicates the company is currently unprofitable.
BTCY Growth Metrics (YoY)
BTCY Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $3.6M | -$717.1K | $-0.04 |
| Q2 2026 | $3.3M | -$690.9K | $-0.03 |
| Q1 2026 | $3.2M | -$672.0K | $-0.03 |
| Q3 2025 | $3.0M | -$1.2M | $-0.05 |
| Q2 2025 | $2.9M | -$1.6M | $-0.07 |
| Q1 2025 | $3.0M | -$3.4M | $-0.41 |
| Q3 2024 | $2.5M | -$2.8M | $-0.34 |
| Q2 2024 | $2.4M | -$3.7M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BTCY Capital Allocation
BTCY SEC Filings
Access official SEC EDGAR filings for BIOTRICITY INC. (CIK: 0001630113)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BTCY
What is the AI rating for BTCY?
BIOTRICITY INC. (BTCY) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BTCY's key strengths?
Exceptional gross margin of 81.3% indicates strong pricing power and product unit economics. Positive operating income of $996.7K demonstrates some operational profitability at the EBIT level.
What are the risks of investing in BTCY?
Negative stockholders' equity of -$34.2M represents technical insolvency and existential bankruptcy risk. Severe liquidity crisis with current ratio of 0.21x and only $256.4K cash against $38.2M total liabilities.
What is BTCY's revenue and growth?
BIOTRICITY INC. reported revenue of $11.7M.
Does BTCY pay dividends?
BIOTRICITY INC. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find BTCY SEC filings?
Official SEC filings for BIOTRICITY INC. (CIK: 0001630113) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BTCY's EPS?
BIOTRICITY INC. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.